Skip to content

The clinical study of assessment of liver segment function with Gd-EOB-DTPA-enhanced hepatic MRI

The clinical study of assessment of liver segment function with Gd-EOB-DTPA-enhanced hepatic MRI

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DCD-15006068
Enrollment
Unknown
Registered
2015-01-14
Start date
2015-05-01
Completion date
Unknown
Last updated
2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

HCC group :Gd-EOB-DTPA-enhanced MRI
healthy group :Gd-EOB-DTPA-enhanced MRI

Sponsors

Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. To be aged between 18-70; follow the standard of AASLD, first diagonosis of HCC, BCLC-A to BCLC-B; 2. no obvious distant metastasis, prediction of major liver resection(>3 segment); 3. Child A or B; 4. no allergic response to contrast, before operation, have the Gd Eob DTPA-enhanced MRI in 4 weeks,ICG and CT liver volume measurement in 1 weeks; 5. have the liver basic diseases; 6. no abnormal cardiopulmonary function; 7. avoid the harmful operation to the liver function during operative time; 8. the patients know the disease condition and the treatment project and the risk of surgery; 9. all volunteers,signing the informed consent form for clinical trial.

Exclusion criteria

Exclusion criteria: 1. have the difficult to follow up, such as :foreign,HK,macao,taiwan; 2. patients who refuse to sign the informed consent form; 3. uncertain clinical HCC diagnosis; 4. allergic to the contrast; 5. early recurrence and metastasis result in death postoperative; 6. BCLC-C or Child C; 7. have mild liver resection (<3 segment); 8. have the renal failure; 9. not primary hepatic tumor.

Design outcomes

Primary

MeasureTime frame
hepatic extraction fraction;clearance of indocyanine green;CT liver volume measurement;pathological grade of liver cirrhosis;

Secondary

MeasureTime frame
tumor location;tumor size;tumor number;tumor pathological;HBV-DNA;blood loss intraoperative;time of operation;time of hepatic hilar occlusion;

Countries

China

Contacts

Public ContactLi Xuesong
anzscd1979@163.com+86 18580207919

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026